ShenZhen GTJA Investment Group
ShenZhen GTJA Investment Group, established in 2001 by Guotai Junan Securities and several listed enterprises, is a prominent investment firm based in China. The group focuses on direct investments and venture capital, targeting companies in sectors such as telecommunications, media, technology, and healthcare. With a commitment to fostering innovation and growth, ShenZhen GTJA plays a significant role in supporting the development of emerging businesses within these industries.
Top Stages
Past deals in Rotterdam
Harbour BioMed
Series C in 2020
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.